Manganese in Women With Encephalopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00985010|
Recruitment Status : Terminated (The authors finished their jobs in the hospitals where the study was begun.)
First Posted : September 25, 2009
Results First Posted : September 25, 2009
Last Update Posted : November 8, 2016
Report manganese serum levels and mortality in encephalopathic patients.
Patients and participants:
Consecutive patients aged > 18 years, with hepatic encephalopathy and informed consent signed by their families.
Patients' clinical characteristics as well as biochemical tests of renal function, hemoglobin, glucose and albumin levels were obtained as well as a blood sample to analyze manganese levels with a graphite furnace atomic absorption spectrometer.
There is a difference in the manganese levels between male and female patients.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||9 participants|
|Official Title:||Manganese, Possible Factor of Higher Mortality in Women With Encephalopathy|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||January 2005|
|Actual Study Completion Date :||January 2005|
- Clinical Evolution [ Time Frame: six months ]Number of participants who died versus those who remained alive after 6 months of follow up since the first entrance at the Emergency Room
- Manganese Levels [ Time Frame: Up to six months we followed the recruited patients to determine who were still alive ]From encephalopathic patients, we took individual blood samples, analyzed in the biochemistry laboratory at the National Institute of Neurology and Neurosurgery, Mexico, City, with a graphite furnace atomic absorption spectrometer, according to the technique reported by Pleban.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00985010
|General Hospital "Dr. Darío Fernández Fierro"|
|Mexico, D.f., Mexico, 03900|
|Principal Investigator:||Hugo Mendieta Zerón, PhD||Materno-Perinatal Hospital of the State of Mexico|
|Study Director:||Camilo Rios Castañeda, PhD||National Institute of Neurology and Neurosurgery|
|Study Chair:||Mónica Rodríguez Rodríguez, MD||General Hospital "Dr. Darío Fernández Fierro"|